Value of functional in-vivo endpoints in preclinical radiation research

Drug development in cancer research, both for drug treatment alone or in combination with radiotherapy, is suffering from a very high attrition rate after pre-clinical development and during early clinical trials. From first-in-man to clinical approval of a new drug in oncology, the success rate declines down to 5%. After phase II clinical trials ≈70% of all treatments are not further developed [1]. Besides the major impact on cost-efficacy in the healthcare system, this may also be an ethical problem concerning the use of experimental animals and the burden for participants in clinical trials.
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Guidelines Source Type: research